MedTrace Logo

The Oslo Study of Visual Impairment After Stroke (StrokeVIS)

NCT05809973 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2025-10-01

No results posted yet for this study

Summary

Longitudinal, prospective, single-center observational study of visual impairment after stroke.

Population: Patients admitted with acute ischemic stroke at the Regional Stroke Unit at Oslo University Hospital who are assessed to not have more serious neurological deficits than to be eligible for a prospective observational study of visual impairment. National Institute of Health Stroke Scale (NIHSS) will be used for screening of the patients eligible for the study with cut off of NIHSS 20. Based on the number of patients admitted to our center to include 120 patients in the StrokeVIS study.

The study aims are:

1. To determine the prevalence of visual impairment in stroke patients in the acute phase and after 3 months.
2. To compare visual impairment in those treated with EVT and those not.
3. To determine the sensitivity and specificity of the Vision Screening Assessment (VISA) tool for detection of visual impairment in stroke patients.
4. To assess possible association between brain MRI lesions and visual impairment in stroke patients in the acute phase.

6\) To assess any cognitive deficits at 3-month follow-up that could impact visual function.

Inclusion criteria:

1. Acute ischemic stroke and NIHSS \< 20
2. Age ≥18 years.
3. Written informed consent of the patient or oral informed consent witnessed by a doctor.

Exclusion criteria:

1. NIHSS \< 20
2. No willingness and ability of the patient to participate in all baseline and follow-up examinations.

Duration of study participation: 3 months.

Conditions

  • Stroke, Acute

Interventions

DIAGNOSTIC_TEST

VISA tool

Validation of VISA

Sponsors & Collaborators

  • University of Liverpool

    collaborator OTHER

  • University of South-Eastern Norway

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2024-05-21
Completion
2024-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05809973 on ClinicalTrials.gov